30-Apr-2025 3:05 PM CST - Business Wire Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25%
10-Apr-2025 3:05 PM CST - Business Wire Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com. The webcast will
20-Feb-2025 3:05 PM CST - Business Wire Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, a
10-Feb-2025 6:00 AM CST - Business Wire Guardant Health to Participate in Upcoming Investor Conferences Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Tim
30-Jan-2025 3:05 PM CST - Business Wire Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com.
13-Jan-2025 6:00 AM CST - Business Wire Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of approximately $200 million, an increase of 29% Reported approximately 57,300 oncology clinical tests (excluding Shield
2-Jan-2025 3:05 PM CST - Business Wire Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Healths management is scheduled to present and participate in a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the Investors section
6-Nov-2024 3:05 PM CST - Business Wire Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excluding Shield) and 10,500 biopharma tests in the third quarter of 2024, representing increases of 21% and 40%, respectively
15-Oct-2024 3:05 PM CST - Business Wire Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com. The webcast wi
30-Apr-2025 3:05 PM CST - Business Wire Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25%
10-Apr-2025 3:05 PM CST - Business Wire Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com. The webcast will
20-Feb-2025 3:05 PM CST - Business Wire Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, a
10-Feb-2025 6:00 AM CST - Business Wire Guardant Health to Participate in Upcoming Investor Conferences Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Tim
30-Jan-2025 3:05 PM CST - Business Wire Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com.
13-Jan-2025 6:00 AM CST - Business Wire Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of approximately $200 million, an increase of 29% Reported approximately 57,300 oncology clinical tests (excluding Shield
2-Jan-2025 3:05 PM CST - Business Wire Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Healths management is scheduled to present and participate in a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the Investors section
6-Nov-2024 3:05 PM CST - Business Wire Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excluding Shield) and 10,500 biopharma tests in the third quarter of 2024, representing increases of 21% and 40%, respectively
15-Oct-2024 3:05 PM CST - Business Wire Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com. The webcast wi
